Combination Study of BMS-754807 and Herceptin® in Patients With Advanced or Metastatic Her-2-positive Breast Cancer
Status:
Completed
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
This is a Phase I/II study to evaluate the safety profile, tolerability, pharmacokinetics and
pharmacodynamics following daily oral doses of 50 to 200 mg of BMS-754807 in combination with
trastuzumab (Herceptin®) in subjects with advanced or metastatic Her-2-positive breast
cancer. In addition, the study is expected to identify the recommended dose or dose range of
BMS-754807 in combination with trastuzumab for Phase II studies and provide preliminary
evidence of anti-tumor activity in Her-2-positive breast cancer subjects after trastuzumab
failure